NULISA CNS Disease Biomarker Platform – The Only High-Plex, High Sensitivity Platform for Investigation of Biomarkers of Neurodegenerative Diseases & Treatment Response
Time: 9:30 am
day: Conference Day One AM
Details:
- NULISA™ combines ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis.
- The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies.
- NULISA enables the unique ability to translate discoveries based on broad profiling into single and low-plex biomarker assays on the same instrumentation
- NULISA single-, low-, and high-plex assays all run fully automated on the ARGO HT System.
- NULISA CNS Disease Panel 120 and Inflammation Panel 250 support exploratory clinical research into therapeutic effects on neurodegenerative disease processes.
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA.
